

PharmLabs San Diego Certificate of Analysis



Sample **Kush - Pink Berry THCP Preroll**

| | | | |
|-------------------------|-------------------|---|-------------------------|
| Delta9 THC 0.14% | THCa 0.06% | Total THC (THCa * 0.877 + THC) 0.20% | Delta8 THC 0.58% |
|-------------------------|-------------------|---|-------------------------|

| | | |
|--|------------------------------|-----------------------------------|
| Sample ID SD260403-198 (126816) | Matrix Flower | Batch ID 260325-KUPR10P-PB |
| Tested for Chapo Extrax | | |
| Sampled - | Received Apr 03, 2026 | Reported Apr 23, 2026 |
| Analyses executed FP-IF20 | | |

Laboratory note: COA Update: 4/23/26 - Batch ID updated per client request.

CANx - Cannabinoids

Analyzed Apr 06, 2026 | Instrument HPLC-VWD | Method SOP-001
 The expanded Uncertainty of the Cannabinoids analysis is approximately ±7.81% at the 95% Confidence Level

| Analyte | LOD mg/g | LOQ mg/g | Result % | Result mg/g |
|---|----------|----------|--------------|---------------|
| 11-Hydroxy-Δ8-Tetrahydrocannabinol (11-Hyd-Δ8-THCV) | 0.013 | 0.041 | ND | ND |
| Cannabidiol (CBDO) | 0.006 | 0.02 | ND | ND |
| Abnormal Cannabidiol (a-CBDO) | 0.013 | 0.038 | ND | ND |
| (+/-)-9B-Hydroxy-Hexahydrocannabinol (9b-HHC) | 0.015 | 0.045 | ND | ND |
| 11-Hydroxy-Δ8-Tetrahydrocannabinol (11-Hyd-Δ8-THC) | 0.015 | 0.045 | ND | ND |
| Cannabidiolic Acid (CBDA) | 0.033 | 0.16 | ND | ND |
| Cannabigerol Acid (CBGA) | 0.033 | 0.16 | 13.82 | 138.24 |
| Cannabigerol (CBG) | 0.048 | 0.16 | 0.52 | 5.19 |
| Cannabidiol (CBD) | 0.069 | 0.229 | 0.02 | 0.24 |
| 1(S)-Tetrahydrocannabinol (1(S)-H4-CBD) | 0.008 | 0.026 | ND | ND |
| 1(R)-Tetrahydrocannabinol (1(R)-H4-CBD) | 0.016 | 0.049 | ND | ND |
| Tetrahydrocannabinol (THCV) | 0.049 | 0.162 | ND | ND |
| Δ8-tetrahydrocannabinol (Δ8-THCV) | 0.012 | 0.036 | ND | ND |
| Cannabidiolhexol (CBDH) | 0.014 | 0.042 | ND | ND |
| Tetrahydrocannabinol (Δ9-THCB) | 0.01 | 0.029 | ND | ND |
| Cannabinol (CBN) | 0.047 | 0.16 | <LOQ | <LOQ |
| Cannabidiophorol (CBDP) | 0.016 | 0.049 | ND | ND |
| exo-THC (exo-THC) | 0.016 | 0.8 | ND | ND |
| Tetrahydrocannabinol (Δ9-THC) | 0.092 | 0.307 | 0.14 | 1.41 |
| Δ8-tetrahydrocannabinol (Δ8-THC) | 0.044 | 0.16 | 0.58 | 5.84 |
| (6aR,9S)-Δ10-Tetrahydrocannabinol ((6aR,9S)-Δ10) | 0.015 | 0.8 | ND | ND |
| Hexahydrocannabinol (S Isomer) (9s-HHC) | 0.017 | 0.8 | ND | ND |
| (6aR,9R)-Δ10-Tetrahydrocannabinol ((6aR,9R)-Δ10) | 0.007 | 0.8 | ND | ND |
| Hexahydrocannabinol (R Isomer) (9r-HHC) | 0.016 | 0.8 | ND | ND |
| Tetrahydrocannabinolic Acid (THCA) | 0.117 | 0.389 | 0.06 | 0.64 |
| Δ9-Tetrahydrocannabinolhexol (Δ9-THCH) | 0.02 | 0.061 | ND | ND |
| Cannabinol Acetate (CBNO) | 0.009 | 0.027 | ND | ND |
| 9(S)-Hexahydrocannabinolic Acid (9(S)-HHCa) | 0.063 | 0.065 | ND | ND |
| 9(R)-Hexahydrocannabinolic Acid (9(R)-HHCa) | 0.191 | 0.196 | ND | ND |
| Δ9-Tetrahydrocannabinophorol (Δ9-THCP) | 0.017 | 0.8 | 0.76 | 7.55 |
| Δ8-Tetrahydrocannabinophorol (Δ8-THCP) | 0.041 | 0.8 | ND | ND |
| Cannabicitran (CBT) | 0.005 | 0.16 | ND | ND |
| Δ8-THC-O-acetate (Δ8-THCO) | 0.076 | 0.8 | ND | ND |
| 9(S)-HHCP (s-HHCP) | 0.013 | 0.041 | ND | ND |
| Δ9-THC-O-acetate (Δ9-THCO) | 0.066 | 0.8 | ND | ND |
| 9(R)-HHCP (r-HHCP) | 0.015 | 0.045 | ND | ND |
| 9(S)-HHC-O-acetate (s-HHCO) | 0.037 | 0.112 | ND | ND |
| 9(R)-HHC-O-acetate (r-HHCO) | 0.031 | 0.093 | ND | ND |
| 3-octyl-Δ8-Tetrahydrocannabinol (Δ8-THC-C8) | 0.021 | 0.062 | ND | ND |
| Total THC (THCa * 0.877 + Δ9THC) | | | 0.20 | 1.97 |
| Total THC + Δ8THC + Δ10THC (THCa * 0.877 + Δ9THC + Δ8THC + Δ10THC) | | | 0.78 | 7.81 |
| Total CBD (CBDA * 0.877 + CBD) | | | 0.02 | 0.24 |
| Total CBG (CBGA * 0.877 + CBG) | | | 12.64 | 126.43 |
| Total HHC (9r-HHC + 9s-HHC) | | | ND | ND |
| Total Cannabinoids Analyzed | | | 14.20 | 142.03 |

*Dry Weight %

HME - Heavy Metals

Analyzed Apr 07, 2026 | Instrument ICP/MSMS | Method SOP-005

| Analyte | LOD ug/g | LOQ ug/g | Result ug/g | Limit ug/g |
|--------------|----------|----------|-------------|------------|
| Arsenic (As) | 0.0009 | 0.0027 | 0.00 | 1.5 |
| Cadmium (Cd) | 0.0005 | 0.0015 | 0.03 | 0.5 |
| Mercury (Hg) | 0.0058 | 0.0174 | 0.00 | 3 |
| Lead (Pb) | 0.0006 | 0.0018 | 0.01 | 0.5 |

UI Unidentified
 ND Not Detected
 N/A Not Applicable
 NT Not Reported
 LOD Limit of Detection
 LOQ Limit of Quantification
 <LOQ Detected
 >LOL Above upper limit of linearity
 CFU/g Colony Forming Units per 1 gram
 TNTC Too Numerous to Count



DEA license: **RP0611043**
 ISO/IEC 17025:2017 Acc. 85368



Scan the QR code to verify authenticity.

Authorized Signature

Brandon Starr

Brandon Starr, Quality Assurance Manager
 Thu, 23 Apr 2026 11:45:43 -0700

PharmLabs San Diego | 6696 Mesa Ridge Rd #A, San Diego, CA 92121 | 619.356.0898 | ISO/IEC 17025:2017 Acc. 85368



PharmLabs hereby states that its Certificates of Analysis (COA) do not certify compliance with any federal, state, or local law or regulation, including but not limited to the 2018 Farm Bill. This COA is provided solely for informational purposes and is not intended for reliance by consumers or purchasers of a product. This report shall not be reproduced, except in full, without the prior written approval of PharmLabs. This report is not intended to diagnose, treat, cure, or prevent any disease. Results apply only to the specific sample(s) and batch(es) identified on this COA and do not represent any other lot, batch, or product from the client. Measurement of uncertainty is available upon request and, when legally required, has been reported on the certificate. PharmLabs makes no representation or warranty, express or implied, regarding the tested product's safety, efficacy, quality, merchantability, or fitness for a particular purpose. PharmLabs expressly disclaims any liability for damages, claims, costs, or expenses arising out of the use, misuse, or reliance upon this COA by any party. PharmLabs relies on information provided by the client regarding the identity, sampling, and chain of custody of the submitted material. PharmLabs assumes no responsibility for errors, omissions, or misrepresentations in such information. It is the sole responsibility of the client to determine and ensure the compliance of their product(s) with all applicable federal, state, and local laws and regulations. This COA may not be used in whole or in part for marketing, advertising, promotional, or labeling purposes without the prior written consent of PharmLabs. This COA is valid only as of the date of issuance and does not guarantee the stability or continued conformity of the tested product beyond that date. Any dispute arising out of or related to this COA shall be governed by the laws of the State of California, without regard to its conflict of laws principles.

MIBIG - Microbial

Analyzed Apr 06, 2026 | Instrument Plating | Method SOP-007

| Analyte | LOD CFU/g | LOQ CFU/g | Result CFU/g | Limit CFU/g |
|--|-----------|-----------|--------------|-------------|
| Shiga toxin-producing Escherichia Coli | 1.0 | 1.0 | Negative | 1 |
| Salmonella spp. | 1.0 | 1.0 | Negative | 1 |
| Aspergillus fumigatus | 1.0 | 1.0 | Negative | 1 |
| Aspergillus flavus | 1.0 | 1.0 | Negative | 1 |
| Aspergillus niger | 1.0 | 1.0 | Negative | 1 |
| Aspergillus terreus | 1.0 | 1.0 | Negative | 1 |

MTO - Mycotoxin

Analyzed Apr 08, 2026 | Instrument LC/MSMS | Method SOP-004

| Analyte | LOD ug/kg | LOQ ug/kg | Result ug/kg | Limit ug/kg | Analyte | LOD ug/kg | LOQ ug/kg | Result ug/kg | Limit ug/kg |
|--------------|-----------|-----------|--------------|-------------|------------------|-----------|-----------|--------------|-------------|
| Ochratoxin A | 5.0 | 20.0 | ND | 20 | Aflatoxin B1 | 2.5 | 5.0 | ND | - |
| Aflatoxin B2 | 2.5 | 5.0 | ND | - | Aflatoxin G1 | 2.5 | 5.0 | ND | - |
| Aflatoxin G2 | 2.5 | 5.0 | ND | - | Total Aflatoxins | 10.0 | 20.0 | ND | 20 |

UI Unidentified
 ND Not Detected
 N/A Not Applicable
 NT Not Reported
 LOD Limit of Detection
 LOQ Limit of Quantification
 <LOQ Detected
 >ULOL Above upper limit of linearity
 CFU/g Colony Forming Units per 1 gram
 TNTC Too Numerous to Count



DEA license: **RP0611043**
 ISO/IEC 17025:2017 Acc. 85368



Scan the QR code to verify authenticity.

Authorized Signature

Brandon Starr

Brandon Starr, Quality Assurance Manager
 Thu, 23 Apr 2026 11:45:43 -0700

PharmLabs San Diego | 6696 Mesa Ridge Rd #A, San Diego, CA 92121 | 619.356.0898 | ISO/IEC 17025:2017 Acc. 85368



PharmLabs hereby states that its Certificates of Analysis (COA) do not certify compliance with any federal, state, or local law or regulation, including but not limited to the 209 Form Bill. This COA is provided solely for informational purposes and is not intended for reliance by consumers or purchasers of a product. This report shall not be reproduced, except in full, without the prior written approval of PharmLabs. This report is not intended to diagnose, treat, cure, or prevent any disease. Results apply only to the specific sample(s) and batch(es) identified on this COA and do not represent any other lot, batch, or product from the client. Measurement of uncertainty is available upon request and, when legally required, has been reported on the certificate. PharmLabs makes no representation or warranty, express or implied, regarding the tested product's safety, efficacy, quality, merchantability, or fitness for a particular purpose. PharmLabs expressly disclaims any liability for damages, claims, costs, or expenses arising out of the use, misuse, or reliance upon this COA by any party. PharmLabs relies on information provided by the client regarding the identity, sampling, and chain of custody of the submitted material. PharmLabs assumes no responsibility for errors, omissions, or misrepresentations in such information. It is the sole responsibility of the client to determine and ensure the compliance of their product(s) with all applicable federal, state, and local laws and regulations. This COA may not be used in whole or in part for marketing, advertising, promotional, or labeling purposes without the prior written consent of PharmLabs. This COA is valid only as of the date of issuance and does not guarantee the stability or continued conformity of the tested product beyond that date. Any dispute arising out of or related to this COA shall be governed by the laws of the State of California, without regard to its conflict of laws principles.

PES - Pesticides

Analyzed Apr 13, 2026 | Instrument LC/MSMS GC/MSMS | Method SOP-003

| Analyte | LOD ug/g | LOQ ug/g | Result ug/g | Limit ug/g | Analyte | LOD ug/g | LOQ ug/g | Result ug/g | Limit ug/g |
|-------------------------|----------|----------|-------------|------------|-----------------------|----------|----------|-------------|------------|
| Aldicarb | 0.01 | 0.02 | ND | | Carbofuran | 0.01 | 0.02 | ND | |
| Dimethoate | 0.01 | 0.02 | ND | | Etofenprox | 0.02 | 0.1 | ND | |
| Fenoxycarb | 0.01 | 0.02 | ND | | Thiachloprid | 0.01 | 0.02 | ND | |
| Daminozide | 0.01 | 0.03 | ND | | Dichlorvos | 0.02 | 0.07 | ND | |
| Imazalil | 0.02 | 0.07 | ND | | Methiocarb | 0.01 | 0.02 | ND | |
| Spiroxamine | 0.01 | 0.02 | ND | | Coumaphos | 0.01 | 0.02 | ND | |
| Fipronil | 0.01 | 0.1 | ND | | Paclobutrazol | 0.01 | 0.03 | ND | |
| Chlorpyrifos | 0.01 | 0.04 | ND | | Ethoprophos (Prophos) | 0.01 | 0.02 | ND | |
| Baygon (Propoxur) | 0.01 | 0.02 | ND | | Chlordane | 0.04 | 0.1 | ND | |
| Chlorfenapyr | 0.03 | 0.1 | ND | | Methyl Parathion | 0.02 | 0.1 | ND | |
| Mevinphos | 0.03 | 0.08 | ND | | Abamectin | 0.03 | 0.08 | ND | |
| Acephate | 0.02 | 0.05 | ND | | Acetamiprid | 0.01 | 0.05 | ND | |
| Azoxystrobin | 0.01 | 0.02 | ND | | Bifentazate | 0.01 | 0.05 | ND | |
| Bifenthrin | 0.02 | 0.35 | ND | | Boscalid | 0.01 | 0.03 | ND | |
| Carbaryl | 0.01 | 0.02 | ND | | Chlorantranilprole | 0.01 | 0.04 | ND | |
| Clofentezine | 0.01 | 0.03 | ND | | Diazinon | 0.01 | 0.02 | ND | |
| Dimethomorph | 0.02 | 0.06 | ND | | Etoazole | 0.01 | 0.05 | ND | |
| Fenpyroximate | 0.02 | 0.1 | ND | | Fonicamid | 0.01 | 0.02 | ND | |
| Fludioxonil | 0.01 | 0.05 | ND | | Hexythiazox | 0.01 | 0.03 | ND | |
| Imidacloprid | 0.01 | 0.05 | ND | | Kresoxim-methyl | 0.01 | 0.03 | ND | |
| Malathion | 0.01 | 0.05 | ND | | Metalaxyl | 0.01 | 0.02 | ND | |
| Methomyl | 0.02 | 0.05 | ND | | Myclobutanil | 0.02 | 0.07 | ND | |
| Naled | 0.01 | 0.02 | ND | | Oxamyl | 0.01 | 0.02 | ND | |
| Permethrin | 0.01 | 0.02 | ND | | Phosmet | 0.01 | 0.02 | ND | |
| Piperonyl Butoxide | 0.02 | 0.06 | ND | | Propiconazole | 0.03 | 0.08 | ND | |
| Prallethrin | 0.02 | 0.05 | ND | | Pyrethrin | 0.05 | 0.41 | ND | |
| Pyridaben | 0.02 | 0.07 | ND | | Spinosad A | 0.01 | 0.05 | ND | |
| Spinosad D | 0.01 | 0.05 | ND | | Spiromesifen | 0.02 | 0.06 | ND | |
| Spirotetramat | 0.01 | 0.02 | ND | | Tebuconazole | 0.01 | 0.02 | ND | |
| Thiamethoxam | 0.01 | 0.02 | ND | | Trifloxystrobin | 0.01 | 0.02 | ND | |
| Acequinocyl | 0.02 | 0.09 | ND | | Captan | 0.01 | 0.02 | ND | |
| Cypermethrin | 0.02 | 0.1 | ND | | Cyfluthrin | 0.04 | 0.1 | ND | |
| Fenhexamid | 0.02 | 0.07 | ND | | Spinetoram J,L | 0.02 | 0.07 | ND | |
| Pentachloronitrobenzene | 0.01 | 0.1 | ND | | | | | | |

FVI - Filth & Foreign Material Inspection

Analyzed Apr 03, 2026 | Instrument Microscope | Method SOP-010

| Analyte / Limit | Result | Analyte / Limit | Result |
|--|--------|--|--------|
| > 1/4 of the total sample area covered by sand, soil, cinders, or dirt | ND | > 1/4 of the total sample area covered by mold | ND |
| > 1 insect fragment, 1 hair, or 1 count mammalian excreta per 3g | ND | > 1/4 of the total sample area covered by an imbedded foreign material | ND |

MWA - Moisture Content & Water Activity

Analyzed Apr 06, 2026 | Instrument Chilled-mirror Dewpoint and Capacitance | Method SOP-008

| Analyte | LOD a _w | LOQ a _w | Result | Limit | Analyte | LOD % M/w | LOQ % M/w | Result | Limit |
|---------------------|--------------------|--------------------|---------------------|---------------------|----------------|-----------|-----------|----------|---------|
| Water Activity (WA) | 0.03 | 0.03 | 0.56 a _w | 0.85 a _w | Moisture (Moi) | 0.0 | 0.0 | 8.0 % Mw | 13 % Mw |

UI Unidentified
 ND Not Detected
 N/A Not Applicable
 NT Not Reported
 LOD Limit of Detection
 LOQ Limit of Quantification
 <LOQ Detected
 >ULOL Above upper limit of linearity
 CFU/g Colony Forming Units per 1 gram
 TNTC Too Numerous to Count



DEA license: RP0611043
 ISO/IEC 17025:2017 Acc. 85368



Scan the QR code to verify authenticity.

Authorized Signature

Brandon Starr

Brandon Starr, Quality Assurance Manager
 Thu, 23 Apr 2026 11:45:43 -0700

PharmLabs San Diego | 6696 Mesa Ridge Rd #A, San Diego, CA 92121 | 619.356.0898 | ISO/IEC 17025:2017 Acc. 85368



PharmLabs hereby states that its Certificates of Analysis (COA) do not certify compliance with any federal, state, or local law or regulation, including but not limited to the 209 Form Bill. This COA is provided solely for informational purposes and is not intended for reliance by consumers or purchasers of a product. This report shall not be reproduced, except in full, without the prior written approval of PharmLabs. This report is not intended to diagnose, treat, cure, or prevent any disease. Results apply only to the specific sample(s) and batch(es) identified on this COA and do not represent any other lot, batch, or product from the client. Measurement of uncertainty is available upon request and, when legally required, has been reported on the certificate. PharmLabs makes no representation or warranty, express or implied, regarding the tested product's safety, efficacy, quality, merchantability, or fitness for a particular purpose. PharmLabs expressly disclaims any liability for damages, claims, costs, or expenses arising out of the use, misuse, or reliance upon this COA by any party. PharmLabs relies on information provided by the client regarding the identity, sampling, and chain of custody of the submitted material. PharmLabs assumes no responsibility for errors, omissions, or misrepresentations in such information. It is the sole responsibility of the client to determine and ensure the compliance of their product(s) with all applicable federal, state, and local laws and regulations. This COA may not be used in whole or in part for marketing, advertising, promotional, or labeling purposes without the prior written consent of PharmLabs. This COA is valid only as of the date of issuance and does not guarantee the stability or continued conformity of the tested product beyond that date. Any dispute arising out of or related to this COA shall be governed by the laws of the State of California, without regard to its conflict of laws principles.